为满足公司生产经营需要，扩大公司经营范围，拟在公司经营范围的基础上 增加"卫生用品和一次性使用医疗用品销售、化妆品批发、化妆品零售、日用化 学产品销售、日用品批发、日用品销售、个人卫生用品销售、特殊医学用途配方 食品销售"和"食品销售（仅销售预包装食品）、食品互联网销售（仅销售预包 装食品）、保健食品（预包装）销售、互联网销售（除销售需要许可的商品）"， 公司的经营范围以登记机关最终核准的内容为准。 | 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-101 | | --- | --- | --- | | 债券代码:113601 | 债券简称:塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于增加公司经营范围及相应修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 塞力斯医疗科技集团股份有限公司（以下简称"公司"）于 2025 年 12 月 22 日召开公司第五届董事会第二十四次会议，审议通过了《关于增加公司经营 范围及相应修订<公司章程>的议案》，该议案尚需提交公司 2026 ...

证券代码：603716 证券简称：塞力医疗 公告编号：2025-102 塞力斯医疗科技集团股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东会类型和届次 2026年第一次临时股东会 召开的日期时间：2026 年 1 月 7 日 14 点 00 分 召开地点：公司（武汉市东西湖区金山大道 1310 号）A 栋 A 会议室 网络投票起止时间：自2026 年 1 月 7 日 至2026 年 1 月 7 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者 的投票，应按照《上海证券交易所上市公司自律监管指引第 1 ...

重要内容提示： 一、董事会会议召开情况 | 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-100 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 第五届董事会第二十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 塞力斯医疗科技集团股份有限公司(以下简称"公司"）2025 年 12 月 17 日 以邮件方式发送第五届董事会第二十四次会议通知，会议于 2025 年 12 月 22 日 在公司 A 栋 C 会议室以现场和通讯相结合的方式召开。本次会议应到董事 9 人， 实到董事 9 人，会议由董事长温伟先生主持，公司全体高级管理人员列席了会议。 本次董事会经过了适当的通知程序，会议的召集、召开和表决程序符合《公 司法》等相关法律法规和《公司章程》的规定，会议及通过的决议合法有效。 为 0 票。 本议案尚需提交股东会审议。 （二）审议通过《关于提请召开 2026 年第一次临时股东会的议案》 二、董事会会议 ...

Core Viewpoint - The stock of Sely Medical has shown significant volatility, with a year-to-date increase of 209.42%, but a recent decline over the past 60 days of 27.63% [1][2]. Group 1: Stock Performance - As of December 19, Sely Medical's stock price was 22.34 yuan per share, with a trading volume of 3.55 billion yuan and a turnover rate of 7.71%, leading to a total market capitalization of 46.95 billion yuan [1]. - The stock has experienced a net outflow of 16.97 million yuan from major funds, with large orders buying 47.49 million yuan and selling 59.06 million yuan [1]. - The stock has appeared on the daily trading leaderboard 37 times this year, with the most recent appearance on August 26, where it recorded a net purchase of 146 million yuan [1]. Group 2: Company Overview - Sely Medical, established on February 23, 2004, and listed on October 31, 2016, is based in Wuhan, Hubei Province, and specializes in medical testing services and in vitro diagnostic products [2]. - The company's revenue composition includes 39.91% from IVD business, 38.01% from SPD business, and 22.08% from pure sales [2]. - The company operates within the pharmaceutical and biological industry, specifically in medical commerce and distribution, with concepts including antigen testing and smart healthcare [2]. Group 3: Financial Performance - For the period from January to September 2025, Sely Medical reported a revenue of 857 million yuan, a year-on-year decrease of 39.64%, and a net profit attributable to shareholders of -87.24 million yuan, down 55.72% year-on-year [2]. - Since its A-share listing, Sely Medical has distributed a total of 27.07 million yuan in dividends, with no dividends paid in the last three years [3]. - As of September 30, 2025, the top ten circulating shareholders included several new institutional investors, indicating a shift in shareholder composition [3].

早盘AI医疗概念震荡回升，华人健康涨近15%，此前鹭燕医药2连板，美年健康、安必平、成都先导、 塞力医疗跟涨。 ...

Group 1 - The core point of the article is that Sely Medical (603716) reported a total of 70,386 shareholders as of December 10 [1]

Core Viewpoint - The A-share pharmaceutical retail sector has experienced a significant rise, with the overall sector increasing by 5.73%, driven by renewed market recognition of the long-term growth logic in the pharmaceutical commercial industry [1][4]. Group 1: Market Performance - The pharmaceutical commercial sector saw a strong performance, with several stocks hitting the daily limit, including Huaren Health and Yiyuan Group, indicating a broad-based rally within the sector [1]. - The demand for protective products has directly translated into increased sales for retail pharmacies, effectively supporting the industry's overall prosperity [1]. Group 2: Industry Dynamics - The pharmaceutical retail industry is transitioning from rapid expansion to a phase of consolidation, with a notable decrease in the number of physical pharmacies, which has been declining for two consecutive quarters since Q4 2024 [2][3]. - The top 10 chain pharmacies are exhibiting significantly lower closure rates compared to smaller chains, leading to a concentration of market share among leading companies [3]. Group 3: Future Outlook - The growth path for industry leaders is becoming clearer, driven by both internal growth through improved product structure and external growth via mergers and acquisitions [3]. - Analysts believe that the recent surge in the pharmaceutical commercial sector reflects a re-evaluation of the industry's value, with a shift from being seen merely as "transporters" to key nodes in the health service ecosystem [4].

Core Viewpoint - The DRG/DIP concept sector experienced a significant increase of 3.87%, leading the market in terms of growth, with notable performances from stocks such as Jiahe Meikang and Saily Medical, which reached their daily limit up [1][2]. Group 1: Market Performance - The DRG/DIP concept sector had 19 stocks rising, with Jiahe Meikang hitting a 20% limit up, followed by Saily Medical at limit up, and other notable gainers including Weining Health, Dian Diagnostics, and Sichuang Medical, which rose by 11.11%, 8.65%, and 5.77% respectively [1]. - The sector saw a net inflow of 737 million yuan from main funds, with 17 stocks receiving net inflows, and 11 stocks exceeding 10 million yuan in net inflow [2]. - The top net inflow stock was Weining Health, attracting 347 million yuan, followed by Saily Medical, Rongke Technology, and Jiayuan Technology with net inflows of 166 million yuan, 83.78 million yuan, and 44.88 million yuan respectively [2]. Group 2: Fund Flow Ratios - Saily Medical, Digital Certification, and Weining Health had the highest net inflow ratios, with rates of 29.65%, 13.45%, and 12.89% respectively [3]. - The top stocks in the DRG/DIP concept based on net inflow include Weining Health with a daily increase of 11.11% and a turnover rate of 15.28%, and Saily Medical with a 9.99% increase and a turnover rate of 12.43% [3][4]. - Other notable stocks include Rongke Technology, Jiayuan Technology, and Jiahe Meikang, which also showed positive performance with increases of 0.90%, 3.27%, and 20.01% respectively [4].

Group 1 - The Shanghai Composite Index closed at 3876.97 points, above the five-day moving average, with a change of 0.17% [1] - The total trading volume of A-shares reached 16651.30 billion yuan, with 1187 A-shares breaking through the five-day moving average [1] - Notable stocks with significant deviation rates include Xingchen Technology at 18.73%, Wanlong Optoelectronics at 13.66%, and Deyi Culture at 12.84% [1] Group 2 - Stocks with smaller deviation rates that just crossed the five-day moving average include Dekeli, Tongli Technology, and Hongxing Shares [1] - The top three stocks with the highest daily increase are Xingchen Technology at 30.00%, Wanlong Optoelectronics at 20.02%, and Deyi Culture at 20.05% [1] - The trading turnover rates for these stocks are notably high, with Xingchen Technology at 38.74% and Deyi Culture at 39.21% [1]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：中国基金报 大家好，不好意思，又来找下跌原因了。 隔夜美股科技板块大跌，泰勒以为这次我们会走出独立行情，没想到还是想多了！ A股下跌 12月18日，A股指数普遍下跌，仅沪指一枝独秀。截至收盘，沪指涨0.16%，深成指跌1.29%，创业板指 跌2.17%。 两市共2845只个股上涨，73只个股涨停，2416只个股下跌。 | 880005 涨跌家数 | | | | --- | --- | --- | | 真中 | 涨停 | 13 | | 涨幅 | > 7% | 108 | | 张帽 | 5-7% 1 | 63 | | 涨幅 | 3-5% | 233 | | 涨幅 | 0-3% | 2441 | | 跌幅 | 0-3% | 2090 | | 跌幅 | 3-5% | 243 | | 跌幅 | 5-7% | 59 | | 跌幅 | > 7% | 24 | | 其中 跌停 | | 8 | | | | 2845 2416 | | 下課家發 下渡南城 新聞 | | | | | | 199 | | | | 5460 | | 总成交额 | | 167 ...